earnings
confidence high
sentiment neutral
materiality 0.60
Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing
Edgewise Therapeutics, Inc.
2022-Q2 EPS reported
-$0.67
- Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.
- Cash and marketable securities of $299M as of June 30, 2021, funding pipeline through key milestones.
- EDG-5506 Phase 1 MAD study ongoing; topline data from healthy volunteers and Becker patients expected late 2021.
- Preclinical EDG-002 cardiac modulator for hypertrophic cardiomyopathy progressing with encouraging data.